Kurs
+1,38%
Kurs
+1,38%
Open
58,40
High
58,60
Low
57,00
Close
58,60
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Tid* | ||
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-06 | N/A | Årsstämma |
| 2025-02-12 | 08:30 | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-30 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2024-04-29 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2023-05-04 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2022-05-18 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2021-05-04 | - | Årsstämma |
| 2021-04-16 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-10-29 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2020-05-14 | - | Årsstämma |
| 2020-04-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Extra Bolagsstämma 2019 |
| 2019-05-10 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-07-13 | - | Extra Bolagsstämma 2018 |
| 2018-06-13 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-06-06 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-04-16 08:15:00
Moss, 16 April 2021
Gentian Diagnostics AS announces its results for the first quarter of 2021. The
highlights include:
* Record sales revenue of MNOK 19.6 in 1Q21, a 33 % organic growth. Reported
growth of 24 % on a currency neutral basis as 1Q20 includes revenues from the
subsidiary Pretect AS, which was divested in 2H20.
* Growth of 60 % versus Q1 last year in fCAL® turbo sales.
* Increased commercial momentum for GCAL®, displaying early signs of the next
revenue level, with new routine users in several European countries and new
distribution contracts.
* Expanded NT-proBNP development scope in order to enable industry
standardisation, expected to positively impact adoption rates. New launch date
set to 1Q22.
* Decision to apply for a listing of the shares at Oslo Børs Main market. It is
envisaged that a transfer of the listing from Euronext Growth to the main market
will take place towards the latter part of 1H21.
Please find the report and results presentation enclosed. The documents will
also be made available on www.gentian.no.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525